Research map: Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data

Back to the article

Papers in this map

  1. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis · Ralf Gold · 2012 · 1737 citations · Cited by this paper
  2. Not All Patients Start From the Same Line: Rethinking Outcome Interpretation in Myasthenia Gravis · 2025 · Related
  3. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis · Robert J. Fox · 2012 · 1357 citations · Cited by this paper
  4. Involvement of Regulatory T Cells in the Pathophysiology of Myasthenia Gravis: From a Pediatrician's Perspective · 2026 · Related
  5. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy · G. S. Francis · 2013 · 136 citations · Cited by this paper
  6. Successful Treatment of Refractory Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease With Tocilizumab: A Case Report and Literature Review · 2025 · Related
  7. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis · Luca Prosperini · 2019 · 104 citations · Cited by this paper
  8. Relapse and Neurological Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease: A Retrospective Secondary Analysis of a Japanese Nationwide Epidemiologic Survey · 2026 · Related
  9. Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study · Nele Claes · 2014 · 90 citations · Cited by this paper
  10. Autoimmune Cerebellar Ataxia Following TNF ‐α Inhibitor Therapy for Rheumatoid Arthritis: A Case Report · 2026 · Related
  11. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients · Allison Jordan · 2020 · 85 citations · Cited by this paper
  12. Unveiling the Mysteries of Rare Neuroimmunological Disorders · 2025 · Related
  13. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results · Ralf Gold · 2021 · 78 citations · Cited by this paper
  14. Acute Denervation Revealed by Electromyography, in Conjunction With Normal Appearing Lumbar Spinal Cord in NMOSD : Case Report · 2025 · Related
  15. Efficacy of delayed‐release dimethyl fumarate in relapsing‐remitting multiple sclerosis: integrated analysis of the phase 3 trials · Vissia Viglietta · 2014 · 53 citations · Cited by this paper
  16. Disability, Cognition, and Quality of Life in Individuals With Multiple Sclerosis: A 2‐Year Cohort Study · 2026 · Related
  17. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries · Takahiko Saida · 2019 · 29 citations · Cited by this paper
  18. Pulmonary Nodular Lymphoid Hyperplasia in a Case of Overlapping Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis · 2025 · Related
  19. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension · Hirofumi Ochi · 2018 · 26 citations · Cited by this paper
  20. Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry · 2025 · Related
  21. Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective study · Anna Maunula · 2023 · 22 citations · Cited by this paper
  22. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC · Thomas Berger · 2019 · 21 citations · Cited by this paper
  23. Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study · Krupa Shah Pandey · 2024 · 11 citations · Cited by this paper
  24. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study · Dimethyl Fumarate Study Group · 2020 · 7 citations · Cited by this paper
  25. Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension · Takayuki Kondo · 2019 · 6 citations · Cited by this paper
  26. Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients · Yang Mao‐Draayer · 2024 · 6 citations · Cited by this paper
  27. Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: 2‐Year Post‐Marketing Surveillance Data · Hirofumi Ochi · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)